Baird Financial Group, Inc. Biomarin Pharmaceutical Inc Transaction History

Baird Financial Group, Inc.

$50.2 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $71,597 - $82,847	826 Added 6.5%	13,535 $1.17 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $1,140 - $1,524	-13 Reduced 0.1%	12,709 $1.24 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $5,997 - $7,076	-73 Reduced 0.56%	13,048 $1.11 Million
Q2 2022 Aug 08, 2022	SELL	$71.48 - $86.85 $312,224 - $379,360	-4,368 Reduced 24.98%	13,121 $1.09 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $52,070 - $64,975	-701 Reduced 3.85%	17,489 $1.35 Million
Q4 2021 Feb 09, 2022	SELL	$71.72 - $91.47 $12,622 - $16,098	-176 Reduced 0.96%	18,190 $1.61 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $4,785 - $5,470	64 Added 0.35%	18,366 $1.42 Million
Q2 2021 Aug 11, 2021	SELL	$75.51 - $84.79 $20.2 Million - $22.7 Million	-267,677 Reduced 93.6%	18,302 $1.53 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $300,564 - $364,755	-4,022 Reduced 1.39%	285,979 $21.6 Million
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $282,598 - $351,058	3,892 Added 1.36%	290,001 $25.4 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $20.4 Million - $37.2 Million	283,742 Added 11987.41%	286,109 $21.8 Million
Q2 2020 Oct 22, 2020	SELL	$79.55 - $124.22 $43,911 - $68,569	-552 Reduced 18.91%	2,367 $292,000
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $39,615 - $61,861	498 Added 20.57%	2,919 $247,000
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $61,735 - $83,775	-865 Reduced 26.32%	2,421 $204,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $2.02 Million - $2.71 Million	-31,407 Reduced 90.53%	3,286 $278,000
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $1.11 Million - $1.41 Million	-16,509 Reduced 32.24%	34,693 $2.34 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $450,040 - $525,933	-5,601 Reduced 9.86%	51,202 $4.39 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $147,181 - $172,387	1,748 Added 3.18%	56,803 $5.05 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $491,498 - $650,527	6,133 Added 12.54%	55,055 $4.69 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $135,150 - $152,131	-1,439 Reduced 2.86%	48,922 $4.83 Million
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $361,959 - $471,580	4,762 Added 10.44%	50,361 $4.74 Million
Q1 2018 May 14, 2018	SELL	$77.67 - $92.63 $253,592 - $302,436	-3,265 Reduced 6.68%	45,599 $3.7 Million
Q4 2017 Feb 09, 2018	SELL	$80.76 - $95.13 $887,310 - $1.05 Million	-10,987 Reduced 18.36%	48,864 $4.36 Million
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $8,704 - $10,254	-108 Reduced 0.18%	59,851 $5.57 Million
Q2 2017 Aug 14, 2017	BUY	N/A	59,959	59,959 $5.45 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.

Account